Sign up
Pharma Capital

Pressure BioSciences' latest Barocycler machine's credentials featured at scientific meetings

The machine can process and analyse under pressure up to 16 samples simultaneously, potentially leading to the discovery of new drugs and treatments.
1507651887_genomics.jpg
The group develops and sells proprietary lab instruments to the life sciences sample preparation market

Pressure cycling technology (PCT) specialist Pressure BioSciences Inc (OTCMKTS:PBIO) says its recently released Barocycler 2320EXTREME instrument has received plaudits at several European scientific meetings - boosting its potential in the European biopharma markets.

The machine can process and analyse under pressure up to 16 samples simultaneously, potentially leading to the discovery of new drugs and treatments.

It is estimated that there are over 1bn FFPE (formalin-fixed, paraffin-embedded) tissue samples in the world, collected over a span of many decades," says Dr Nathan Lawrence, the vice president of marketing and sales at Pressure BioSciences.

"Complete clinical histories for such samples are often available, including such important data as disease progression and outcome, medications taken, and symptoms.

"More effective analyses of such samples, enabled by methods such as PCT, is expected to result in a bonanza of new and important biomarker discoveries. These discoveries open pivotal opportunities for development of new drugs, therapies, and disease-prevention strategies."

SCIEX, the co-marketing partner of PBI, organized an all-day seminar focused on the latest applications of mass spectrometry in digital biobanking in Munich, which discussed the Barocycler 2320EXT.

The 55th European High Pressure Research Group  took place in Poznan, Poland and looked at high pressure research.

The 16th Human Proteome Organization (HUPO) World Congress took place in Dublin, Ireland.

The OTCQB-listed firm develops and sells proprietary laboratory instrumentation and associated consumables to the US$6bn life sciences sample preparation market.

Shares added 3.24% to US$4.14 in New York.

View full PBIO profile

Pressure BioSciences Inc Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.